Antineoplastic Agents - Administration & dosage
Research News and Information

Monday, November 23, 2009

Allogeneic hematopoietic cell transplantation (allogeneic HCT) for treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL).

13 Dec 2009 BACKGROUND: Allogeneic hematopoietic cell transplant (HCT) with best available donor for children with Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL) has previously been considered standard practice. Since the introduction of ... Read more...

A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a Children's Oncology Group report.

29 Nov 2009 BACKGROUND: Despite the increasing cure rates for children with acute lymphoblastic leukemia (ALL), patients who relapse continue to have poor prognosis. The Children's Oncology Group (COG) conducted a limited institution Phase II trial of ... Read more...

From glioblastoma to gangliocytoma: an unforeseen but welcome shift in biological behavior.

30 Oct 2009 The prognosis in children harboring a glioblastoma multiforme (GBM) is usually poor. Few GBMs in children, however, seem to respond quite well to adjuvant chemotherapy. The biological basis for such chemotherapy sensitivity remains uncertain. In ... Read more...

Latest indexed articles for 'Antineoplastic Agents - Administration & dosage'

These are the very latest articles for this heading:

• Allogeneic hematopoietic cell transplantation (allogeneic HCT) for treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). 13 Dec 2009
• A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a Children's Oncology Group report. 29 Nov 2009
• From glioblastoma to gangliocytoma: an unforeseen but welcome shift in biological behavior. 30 Oct 2009
• Timing of breast cancer treatments with oocyte retrieval and embryo cryopreservation. 30 Oct 2009
• Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. 20 Oct 2009
• Chronic natural killer-cell lymphocytosis successfully treated with alemtuzumab. 13 Oct 2009
• Postsynthetic modifications of iron-carboxylate nanoscale metal-organic frameworks for imaging and drug delivery. 12 Oct 2009
• Use of archived specimens in evaluation of prognostic and predictive biomarkers. 6 Oct 2009
• Multivalent display of quinic acid based ligands for targeting E-selectin expressing cells. 6 Oct 2009
• Tumor lysis syndrome after transarterial chemoembolization of hepatocellular carcinoma: case reports and literature review. 5 Oct 2009
• Analysis of risk factors for central venous port failure in cancer patients. 5 Oct 2009
• Chemoradiotherapy with weekly cisplatin 40 mg/m(2) in 103 head-and-neck cancer patients: a cumulative dose-effect analysis. 4 Oct 2009
• Lamivudine for the prevention of hepatitis B virus reactivation after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with advanced or relapsed non-Hodgkin's lymphoma single institution experience. 29 Sep 2009
• Combination treatment of Cetuximab and photodynamic therapy in SNU-1041 squamous cancer cell line. 29 Sep 2009
• Preliminary in vivo evaluation of the protein transduction domain-modified ATTEMPTS approach in enhancing asparaginase therapy. 29 Sep 2009
• Case report. Intra-arterial chemotherapy for laryngeal cancer via a non-bifurcating carotid artery. 29 Sep 2009
• [Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC): evaluation, prevention and policies to avoid occupational exposure for operating room personnel] 29 Sep 2009
• Predictors of complete pathological response after neoadjuvant systemic therapy for breast cancer. 29 Sep 2009
• Diffusion-weighted MRI of advanced hepatocellular carcinoma during sorafenib treatment: initial results. 29 Sep 2009
• Lessons from the lung for targeted anticancer drugs. 29 Sep 2009

See a longer list of these articles.

Technical information about 'Antineoplastic Agents'

Definition: Substances that inhibit or prevent the proliferation of NEOPLASMS.

Registry Number: 0

Descriptor UI: D000970

Alternative terms: Antineoplastic Agents; Agents, Antineoplastic; Antineoplastics; Antitumor Drugs; Drugs, Antitumor; Antineoplastic Drugs; Drugs, Antineoplastic; Antitumor Agents; Agents, Antitumor;

Related Mesh Headings: Cytotoxins; Infusions, Intra-Arterial; Chemotherapy, Cancer, Regional Perfusion; Tumor Lysis Syndrome; Chemoembolization, Therapeutic; Anticarcinogenic Agents;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D27.505.954.248;

Technical Notes: /admin: various administration procedures are available, as CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; CHEMOEMBOLIZATION, THERAPEUTIC and INFUSIONS, INTRA-ARTERIAL; for combined anticancer agents, ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS is available; Manual 24.4.2.1+